Star Group, L.P. Declares Quarterly Distribution of 18.50 Cents per Unit

Rhea-AI Summary

Star Group (NYSE:SGU) declared a quarterly distribution of $0.1850 per common unit for the three months ended December 31, 2025. The record date is January 26, 2026 and the payment date is February 4, 2026. This distribution covers the quarter ending December 31, 2025 and will be paid to unitholders of record on the stated record date.

Positive

• Declared quarterly distribution of $0.1850 per common unit
• Clear timeline: record date Jan 26, 2026 and payment date Feb 4, 2026

Negative

• None.

Key Figures

Number of abstracts: 8 abstracts Pooled Phase 3 participants: 215 participants Caregivers surveyed: 243 caregivers +5 more

8 metrics

Number of abstracts 8 abstracts Data to be presented at 15th European Epilepsy Congress

Pooled Phase 3 participants 215 participants GWPCARE3 and GWPCARE4 Epidyolex Phase 3 trials in LGS

Caregivers surveyed 243 caregivers BECOME caregiver survey on Epidyolex treatment outcomes

Seizure frequency improvement 87% Caregivers reporting improved seizure frequency with Epidyolex

Seizure severity improvement 81% Caregivers reporting improved seizure severity with Epidyolex

Weekly seizure-free days 68% Caregivers reporting improvement in weekly seizure-free days

Non-seizure domain improvement 84% Improvements in alertness, cognition, executive function

Intention to continue therapy 94% Caregivers planning to continue Epidyolex treatment

Market Reality Check

Price: $12.84 Vol: Volume 12,220 is below 20...

low vol

$12.84 Last Close

Volume Volume 12,220 is below 20-day average of 32,291, indicating muted pre-news activity. low

Technical Trading slightly above 200-day MA of $11.95 with price at $12.24.

Peers on Argus

SGU was nearly flat at +0.08% while peers showed mixed moves: several names like...

SGU was nearly flat at +0.08% while peers showed mixed moves: several names like PARR and DK were up between 0.75% and 2.18%, and WKC was down 1.08%. This points to stock-specific factors rather than a clear sector-wide move.

Historical Context

5 past events · Latest: Dec 08 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 08	Full-year earnings	Positive	-3.1%	Stronger margins and EBITDA but shares fell post-report.
Dec 03	Earnings call notice	Neutral	+0.9%	Scheduling of Q4 results release and webcast.
Oct 16	Distribution declaration	Positive	-0.5%	Announced $0.1850 quarterly distribution to unitholders.
Aug 06	Q3 earnings	Negative	-0.8%	Revenue decline and wider quarterly net loss.
Jul 31	Q3 call notice	Neutral	+0.2%	Announcement of Q3 earnings release and webcast.

Pattern Detected

SGU often shows modest or negative reactions even to objectively positive earnings and distribution announcements, with neutral events drawing small moves.

Recent Company History

Over the last few quarters, Star Group reported generally improving fundamentals, with fiscal 2025 full-year revenue at $1.8 billion and net income of $73.5 million, alongside 22.2% growth in Adjusted EBITDA to $136.4 million. Quarterly results have been more mixed, including a weaker Q3 where revenue declined 7.8% and net loss widened to $16.6 million. The partnership has remained active with regular earnings calls and a recurring quarterly distribution of $0.1850 per unit. Against this backdrop, the latest distribution news fits a pattern of steady capital returns following periodic earnings updates.

Market Pulse Summary

This announcement of a quarterly distribution continues Star Group’s pattern of returning cash to un...

Analysis

This announcement of a quarterly distribution continues Star Group’s pattern of returning cash to unitholders, following prior payments of $0.1850 per unit and regular earnings updates. Context from recent filings shows a business centered on home heating oil and propane with meaningful Adjusted EBITDA of $136.4 million in fiscal 2025. Investors may focus on the sustainability of distributions relative to earnings, customer trends in key regions, acquisition activity, and any changes disclosed in future 8-K, 10-Q, and 10-K filings.

Key Terms

cannabidiol, lennox-gastaut syndrome, dravet syndrome, phase 3, +4 more

8 terms

cannabidiol medical

"Epidiolex/Epidyolex (cannabidiol, 100mg/mL oral solution) and concomitant clobazam."

Cannabidiol (CBD) is a natural compound found in cannabis and hemp plants that does not produce a “high.” Investors watch CBD because it is the active ingredient in many health, wellness, and consumer products, and its value depends on shifting rules, clinical evidence, product approvals, and consumer demand—much like a key ingredient in a popular food or drug that determines shelf placement, pricing, and sales potential.

lennox-gastaut syndrome medical

"patients with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS)"

Lennox-Gastaut syndrome is a severe, long-term form of epilepsy that typically begins in childhood and involves multiple types of hard-to-control seizures, slowed development, and learning difficulties. For investors, it matters because the condition creates ongoing demand for specialized medications, medical devices, and long-term care solutions, so advances in treatments or regulatory approvals can meaningfully affect the commercial value and market prospects of companies working on therapies.

dravet syndrome medical

"patients with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS)"

A rare, severe form of epilepsy that begins in infancy and causes frequent, prolonged seizures, developmental delays, and heightened risk of sudden unexplained death. It is caused by genetic changes that disrupt normal brain electrical activity—like a faulty circuit that repeatedly trips—so standard treatments often work poorly. Investors pay attention because the high unmet need, clear genetic target, and regulatory incentives can make therapies for this condition commercially and clinically significant, but trials are often long and costly.

phase 3 medical

"GWPCARE3 and GWPCARE4 Epidyolex Phase 3 trials will be presented"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

open-label extension medical

"GWPCARE6: A Phase 3 Trial With Open-Label Extension"

An open-label extension is a continuation of a clinical trial where all participants and researchers know which treatment is being given, often after an initial blinded phase. It allows further study of a drug's long-term safety and effectiveness. For investors, it can indicate ongoing interest and confidence in a product's potential, influencing perceptions of its future value.

randomised, controlled trials medical

"post-hoc analysis of data from three randomized, controlled trials"

Randomised, controlled trials are studies that compare a new treatment or intervention against a standard treatment or a placebo by randomly assigning participants to one group or the other, so differences in outcomes are likely due to the intervention rather than chance. For investors, these trials are the most reliable way to show if a drug or medical device works and is safe, and their results often drive regulatory approvals, market value, and commercial prospects—think of it like testing two recipes by randomly giving different versions to groups and seeing which consistently performs better.

ketogenic diet medical

"effect of a ketogenic diet (KD)*, on cannabidiol plasma concentration"

A ketogenic diet is a very low-carbohydrate, high-fat eating plan that shifts the body’s fuel from sugars to fat, causing the liver to produce small molecules called ketones used for energy. Investors care because this diet shapes consumer demand and clinical research for foods, supplements and medical products, and can influence market size, regulatory interest and product development much like a major shift in what powers an economy.

caregiver global impression of change (cgic) medical

"associated with Caregiver Global Impression of Change (CGIC)."

Caregiver Global Impression of Change (CGIC) is a single, overall rating provided by a patient’s caregiver that summarizes whether the patient’s condition has improved, worsened, or stayed the same since the start of a treatment. Think of it as a before-and-after snapshot from someone who lives with the patient; regulators, clinicians, and investors use CGIC to gauge perceived real-world benefit beyond lab tests because it can influence approval decisions, market uptake, and payer reimbursement.

AI-generated analysis. Not financial advice.

STAMFORD, Conn., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Star Group, L.P. (the "Company" or "Star") (NYSE:SGU), a home energy distributor and services provider, today declared its quarterly distribution of $0.1850 per common unit for the three months ended December 31, 2025.

• Record date: January 26, 2026
• Payment date: February 4, 2026

About Star Group, L.P.
Star Group, L.P. is a full service provider specializing in the sale of home heating products and services to residential and commercial customers to heat their homes and buildings. The Company also sells and services heating and air conditioning equipment to its home heating oil and propane customers and, to a lesser extent, provides these offerings to customers outside of its home heating oil and propane customer base. Star also sells diesel, gasoline and home heating oil on a delivery only basis. We believe Star is the nation's largest retail distributor of home heating oil based upon sales volume. Including its propane locations, Star serves customers in the more northern and eastern states within the Northeast and Mid-Atlantic U.S. regions. Additional information is available by obtaining the Company's SEC filings at www.sec.gov and by visiting Star's website at www.stargrouplp.com, where unit holders may request a hard copy of Star’s complete audited financial statements free of charge.

Forward Looking Information
This news release includes "forward-looking statements" which represent the Company’s expectations or beliefs concerning future events that involve risks and uncertainties, including the impact of geopolitical events on wholesale product cost volatility, tariff regimes, including newly imposed U.S. tariffs and any additional responsive non-U.S. tariffs or additional U.S. tariffs, the price and supply of the products that we sell, our ability to purchase sufficient quantities of product to meet our customer’s needs, rapid increases in levels of inflation, the consumption patterns of our customers, our ability to obtain satisfactory gross profit margins, the effect of weather conditions on our financial performance, our ability to obtain new customers and retain existing customers, our ability to make strategic acquisitions, the impact of litigation, natural gas conversions and electrification of heating systems, pandemic and future global health pandemics, recessionary economic conditions, future union relations and the outcome of current and future union negotiations, the impact of current and future governmental regulations, including federal, state and municipal laws restricting greenhouse gases ("GHG") emissions and federal, state and local environmental, health, and safety regulations, the ability to attract and retain employees, customer credit worthiness, counterparty credit worthiness, marketing plans, cyber-attacks, global supply chain issues, labor shortages and new technology, including alternative methods for heating and cooling residences. All statements other than statements of historical facts included in this Report including, without limitation, the statements under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere herein, are forward-looking statements. Without limiting the foregoing, the words “believe,” “anticipate,” “plan,” “expect,” “seek,” “estimate,” and similar expressions are intended to identify forward-looking statements. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct, and actual results may differ materially from those projected as a result of certain risks and uncertainties. These risks and uncertainties include, but are not limited to, those set forth under the heading "Risk Factors" and "Business Strategy" in our Annual Report on Form 10-K (the "Form 10-K") for the fiscal year ended September 30, 2025. Important factors that could cause actual results to differ materially from the Company’s expectations ("Cautionary Statements") are disclosed in this news release and in the Company’s Form 10-K and our Quarterly Reports on Form 10-Q. All subsequent written and oral forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by the Cautionary Statements. Unless otherwise required by law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this news release.

CONTACT:
Star Group, L. P.	Chris Witty
Investor Relations	Darrow Associates
203/328-7310	646/438-9385 or cwitty@darrowir.com

FAQ

What distribution did Star Group (SGU) declare for the quarter ended December 31, 2025?

Star Group declared a quarterly distribution of $0.1850 per common unit for the quarter ended December 31, 2025.

When is the record date for Star Group (SGU) January 2026 distribution?

The record date for the distribution is January 26, 2026.

When will Star Group (SGU) pay the distribution declared in January 2026?

The payment date for the distribution is February 4, 2026.

Which period does the Star Group (SGU) distribution of $0.1850 cover?

The distribution covers the three months ended December 31, 2025.

Who is eligible to receive the Star Group (SGU) distribution paid Feb 4, 2026?

Unitholders of record on January 26, 2026 are eligible to receive the Feb 4, 2026 payment.